Gangliosides inhibit 1251-labeled thyrotropin binding to the thyrotropin receptors on bovine thyroid plasma membranes, on guinea pig retro-orbital tissue plasma membranes, and on human adipocyte membranes. This inhibition by gangliosides is critically altered by the number and location of the sialic acid residues within the ganglioside structure, the efficacy of inhibition having the following order: GD1b > GTI > GM1 > GM2 = GM3 > GD1a. The inhibition results from the interaction of thyrotropin and gangliosides, rather than the interaction of membrane and gangliosides. Fluorescence studies show that the inhibition is associated with a distinct conformational change of the thyrotropin molecule and that the progression from a "noninhibitory conformation" to an "inhibitory conformation" parallels exactly the order of effectiveness in inhibiting 125I-Yabeled thyrotropin binding. The ganglioside inhibition of 1251-labeled thyrotropin binding appears to be hormonally specific in that it is not affected by a umin, glucagon, insulin, prolactin, follicle-stimulating hormone, growth hormone, or corticotropin. The possibility that a ganglioside or ganglioside-like structure is a component of the thyrotropin receptor is suggested by the finding that gangliosides more complex than N-acetylneuraminylgalactosylglucosylceramide are present in bovine thyroid membranes in much higher quantities than have been previously found in extraneural tissue. The finding that the B component of cholera toxin, which also interacts with gangliosides, has a peptide sequence in common with the f, subunit of thyrotropin, suggests that thyrotropin and cholera toxin may be analogous in their mode of action on the membrane.
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In previous studies that detailed the solubilization of the thyrotropin (TSH) receptor from bovine thyroid plasma membranes, tryptic digestion was shown to yield a receptor fragment that exhibited specific TSH binding and had properties similar to those exhibited by the TSH receptor prior to solubilization (1, 2) . This receptor fragment was purified by chromatography over TSH-Sepharose preparations (1, 2) ; it was shown to have a molecular weight of 25,000-30,000 by gel electrophoresis in the presence of sodium dodecyl sulfate (2) , and to contain 30% carbohydrate and 10% sialic acid by weight (1) . The sialic acid was vital to receptor function Abbreviations: TSH, thyrotropin; GM3, N-acetylneuraminylgalactosylglucosylceramide; GM2, N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide; GM1, galactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide; GDla,
since neuraminidase digestion eliminated the ability of both the purified receptor fragment and the crude solubilized receptor preparation to specifically bind TSH (1) .
Recent studies have indicated that gangliosides, glycosphingolipids that contain sialic acid, specifically interact with cholera toxin and that variations in the oligosaccharide structure of the gangliosides influence this interaction (3) (4) (5) . The present report demonstrates that TSH also interacts with gangliosides and that the location and number of the sialic acid residues on the ganglioside molecule is critical to this interaction. The report further shows that there is a sequence homology in the B component of cholera toxin and the ,B subunits of TSH, luteinizing hormone, and human chorionic gonadotropin. It is suggested, therefore, that a ganglioside-like structure is a basic component of glycoprotein hormone receptors and that cholera toxin and the glycoprotein hormones might have a common mechanism by which their message is transmitted to the cell machinery.
MATERIALS AND METHODS
TSH, 125I-labeled TSH, and thyroid plasma membranes were bovine preparations prepared as described (6) (7) (8) (9) . 1251_ labeled TSH binding to plasma membranes was assayed by the filtration techniques already described (8, 9) Gangliosides N-acetylneuraminylgalactosylglucosylceramide (GM3), N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide (GM2), and N-acetylneuraminylgalactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide (GDLa) were obtained as previously described (10) . Gangliosides galactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide (GM,), galactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl-N-acetylneuraminyl) -galactosylglucosylceramide (GD1b), and N-acetylneuraminylgalactosyl-N-acetyl- galactosaminyl-(N-acetylneuraminyl-N-acetylneuraminyl)-galactosylglucosylceramide (GT1) were isolated from commercial preparations (Supelco, Inc., Bellefonte, Pa.) by preparative thin-layer chromatography (11) . After visualizing with iodine vapor, the individual gangliosides were scraped from the plates, eluted with chloroform:methanol:water (10:10:3, vol/vol/vol), taken to dryness under a stream of nitrogen, and redissolved in 0.01 M Tris-acetate, pH 7.0. Each ganglioside used in these experiments was at least 99% pure after rechromatography, visualization with resorcinol reagent, and densitometric analysis (11) . Gangliosides were quantitated from their sialic acid content using a micromodification of the resorcinol method of Svennerholm (12) . Gangliosides were extracted from bovine thyroid membranes, purified by the method of Yu and Ledeen (13) , separated by thin-layer chromatography, visualized with resorcinol reagent, and quantitated by densitometry, as previously described (11) .
Fluorescence measurements were carried out at 25°0 .100 with a Turner model No. 210 spectrofluorometer equipped with a thermostated cell holder. Small aliquots of concentrated ganglioside solutions in 0.01 M Tris-acetate, pH 7.0, were added to TSH solutions which were being magnetically stirred and which contained the same buffer. Identical aliquots of buffer were added to TSH "control" solutions. The excitation and emission wave lengths were 278 nm and 305 nm, respectively. The absorbance of the solutions used for fluorescence measurements never exceeded 0.1 cm-1 at the excitation wave length. TSH concentrations are based on their absorbance at 276.5 nm using an EM = 25,700 liter/mole per cm (14) . N-Acetyltyrosine-NH2 solutions were used to monitor the stability of the instrument. Ganglioside + "2II-labeled TSH 97 4 Ganglioside + membranes without centrifugation before assay 93 5
Ganglioside + membranes followed by centrifugation before assay 0 * In the control experiment where no preincubation was performed (Exp. 1), all components (membranes, gangliosides, and 1251-labeled TSH) were added within 10 sec, mixed, and incubated for a total of 75 min prior to filtration. In Exps. 2, 3, and 4, the noted components were preincubated in assay buffer for 15 min before the missing component, ganglioside, membranes, and 125I-labeled TSH, respectively, were added; the binding assay then proceeded for 60 min before filtration or a total of 75 min from the onset of preincubation. In Exp. 5, after the ganglioside and membranes were preincubated for 15 min, the mixture was centrifuged at 12,000 x g for 15 min to sediment the membranes. The membranes were then resuspended in buffer and the missing component, 125I-labeled TSH, was added. The ganglioside preparation used in these experiments was a mixed preparation (from bovine brain) containing 47% GD1a, 25% GT1, 16% Dib, and 12% GM1; 70 nmol were added. In addition to serving as a control for -Exp. 5, Exp. 2 shows that gangliosides can "chase" bound TSH off the membrane. All procedures were performed at 2-4°.
RESULTS
Gangliosides inhibit 125I-labeled TSH binding to thyroid plasma membranes, and this inhibition is related to the carbohydrate structure of the ganglioside (Fig. 1) . The best inhibitor is GD1b, where two sialic acid residues are located on the internal galactose residue of the oligosaccharide portion of the ganglioside structure. The addition of a sialic acid residue to the terminal galactose residue of the ganglioside structure, as in GT1, reduces the inhibition only slightly; inhibition is nearly eliminated, however, if one of the internal sialic acid residues is simultaneously deleted, as in GD1a.
GM1, the most reactive ganglioside with cholera toxin (3) (4) (5) , is intermediate in its ability to inhibit 125I-labeled TSH binding by comparison to the most reactive and least reactive ganglioside in these experiments, GDib and GDia, respectively., The ganglioside inhibition of TSH binding to thyroid plasma membranes is the result of a specific interaction of ganglioside with TSH rather than of an interaction of gangliosides with plasma membranes. Evidence for the latter conclusion comes from experiments which show no inhibition of binding when gangliosides are preincubated with membranes, prior to exposure to 125I-labeled TSH (Table 1) . Evidence for the specific interaction of TSH and gangliosides has been obtained in multiple separate experiments. In the first, preincubation of 125I-labeled TSH with gangliosides results in a change in the elution pattern of the 125I-labeled TSH when it was subjected to gel filtration chromatography; in contrast, preincubation of 125I-labeled TSH and gangliosides in the presence of a 1000-fold excess of unlabeled TSH prevents the altered elution of the 125I-labeled TSH. Ultracentrifugation experiments confirm the interaction of TSH and ganglioside and suggest that this interaction can result Cell Biology: Mullin et al. (14) . The altered environment thus reflects a conformational change in the TSH molecule independent of whether this results from internalization of the tyrosine residues to a more "buried" location or from externalization to a more "exposed" location. The TSH concentration was 2 X 10-6 M.
in the formation of multimolecular complexes. Thus, at approximately equivalent (l0-5 M) concentrations of GM1 and TSH, the sedimentation value of nearly one-half of the TSH present shifts from 2.5 S to 12.3 S, i.e., a significant portion of the TSH is associated with a complex having a molecular weight of approximately 250,000, given the usual assumptions inherent in relating sedimentation values to molecular mass (15) .
Fluorescence studies indicate that gangliosides induce a conformational change in the TSH molecule and that the conformational change induced by the best inhibitor (GD1b) of the TSH-receptor interaction is distinct from that induced by a minimal inhibitor (GD1a) of this interaction (Fig. 2) . Moreover, these studies show that the ability of a ganglioside to inhibit TSH binding to the receptor correlates directly with ability of the ganglioside to shift the TSH from a "noninhibitory conformation" to an "inhibitory conformation," i.e., the order of ganglioside inhibition of binding most effective to least effective (GDlb > GT1 > GM1 > GM2 = GM3 > GDia) is the same as the order of negative to positive fluorescence changes induced by the gangliosides (Fig. 2) .
The ganglioside-TSH interaction appears to be hormonally specific in that insulin, glucagon, prolactin, growth hormone, follicle-stimulating hormone, and corticotropin do not prevent the ganglioside inhibition of 1251-labeled TSH binding to thyroid plasma membranes ( Table 2 ). Binding studies that have substituted human adipocyte and guinea pig retroorbital tissue plasma membranes for the thyroid plasma membranes have thus far indicated that the inhibition by gangliosides is common to TSH receptors independent of the species or tissue from which these receptors were obtained ( Table 3) .
The ganglioside content of thyroid plasma membranes has been examined (Fig. 3) . There are 5.6 nmol of lipid-bound sialic acid per mg of protein, of which 32% is GM3 and 68% is higher ganglioside homologs. The higher homologs include gangliosides that migrate in the position of GM1, GD1a, GD1b, and GT1; neuraminidase digestion can eliminate the last three of these with a corresponding increase in GM1. This distribution of gangliosides is unusual for extraneural tissues, where GM3 usually predominates (18, 19) . DISCUSSION The present report demonstrates that TSH interacts with gangliosides to prevent binding to specific TSH receptors on plasma membranes. The interaction is critically influenced by the location of the sialic acid residues in the ganglioside structure and results in an altered TSH conformation. The binding and fluorescence data show that the TSH-ganglioside interaction is distinct from that of cholera toxin and gan- The 125I-labeled TSH in these experiments was present at a concentration of approximately 2.0 x 10-9 M; GM1 (50 nmol) was the added ganglioside. Bovine insulin, bovine glucagon, and porcine corticotropin were obtained from Calbiochem, San Diego, Calif. Bovine prolactin, bovine growth hormone, and rat follicle-stimulating hormone were highest purity preparations available from the NIH Endocrinology Study Section, Bethesda, Md. 20014 . The hormones tested above had no effect on '251-labeled TSH binding to membranes at the concentrations tested. The effect of unlabeled bovine TSH and bovine luteinizing hormone could not be accurately evaluated since levels of these hormones which reversed the inhibition also inhibited 1251-labeled TSH binding to the membranes. from bovine thyroid plasma membranes. Thyroid plasma membranes were prepared as described (8, 9) . The gangliosides were extracted using techniques applicable to crude non-neural tissues (13) . Chromatograms were developed and standards prepared as detailed in Materials and Methods.
glioside. Thus GD1b is the best inhibitor of TSH binding, whereas Gm1 is demonstrated to be the best inhibitor of cholera toxin binding (3) (4) (5) . GD1b has, in fact, been reported to be ineffective in blocking the cholera toxin action (20) . Despite their different specificities for gangliosides, an interesting relationship of the cholera toxin B protein and the 13 subunit of TSH may exist. Analysis of the primary sequence of these molecules, as well as of luteinizing hormone and human chorionic gonadotropin, which are glycoprotein hormones similar in structure to TSH, shows a highly significant structural homology among all the peptides in that a common sequence can be readily recognized (Fig. 4) .
The present study raises the possibility that gangliosides are an important structural component of TSH receptors in all tissues or a structural analog of an "active site" important for binding in these membranes. These studies further suggest that by alterations in the location or number of sialic acid residues, the ganglioside structure may be made more or less specific for a particular hormone or for a molecule * The ganglioside used in this experiment was a mixed preparation (see legend to Table 2 ). The ratio of gangliosides to membrane protein was the same as in Fig. 1 . 
FIG. 4 . Sequences of the amino-terminal 41 residues of B component of cholera toxin and of portions of the (3 subunits of TSH, luteinizing hormone (LH), and human chorionic gonadotropin (HCG) defined by positions from the amino-terminal residue of each molecule. The boxed-in residues show a high degree of sequence homology, as measured by a mutation data matrix (21) . The analysis included an evaluation of the remainder of the sequence of the /3 subunits of the glycoprotein hormones as well as a comparison of cholera toxin to the a subunits of these glycoprotein hormones. In none of these cases did a significant homology exist beyond that predicted by random sequence construction. Similarly, insulin and glucagon exhibited no sequence homology. The residue symbols corresponding to the standard residue abbreviations are as follows (21) : A, Ala; P, Pro; D, Asp; T, Thr; S, Ser; L, Leu; I, Ile; V, Val; E, Glu; G, Gly; H, His; C, Cys; N, Asn; M, Met; Q, Gln; Z, Glx; R, Arg; F, Phe; Y, Tyr. respectively) translocates within the membrane domain to interact with adenylate cyclase and to significantly alter ion transport. Such a mechanism is in accord with our previous study (24) suggesting that the TSH (3subunit contains determinants for TSH-receptor binding, whereas the a-subunit does not. It is further in accord with data (24) that indicate that a specific conformation of the TSH molecule is required for adenylate cyclase stimulation and that this conformation, despite a common and interchangeable a subunit, is distinct from the conformation of luteinizing hormone after it interacts with the TSH receptor. The sequence homologies between luteinizing hormone, human chorionic gonadotropin, TSH, and cholera toxin (Fig.  4) raise the possibility that luteinizing hormone and human chorionic gonadotropin also have a similar mechanism of receptor interaction but that each of these agents recognizes carbohydrate sequences distinct from those recognized by TSH or cholera toxin. Each target organ might thus have a receptor with a specific carbohydrate sequence on a ganglioside-like structure. The interaction of the appropriate hormone with this specific oligosaccharide would result in a unique conformational shift such that the a subunit would be placed in the position favored for adenylate cyclase activation in that particular target tissue. Interaction with the wrong hormone would result in a different conformation, an unfavorable position, and no second message. The predictions inherent in this hypothesis are being examined.
